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Abstract  
 
AIM: Smooth muscle cells may be capable of acquiring a myofibroblastic phenotype. To explore 
this hypothesis, we have studied the expression of smoothelin in fibrotic conditions.  
 
METHODS: Normal liver tissue (n = 3) was obtained from macroscopically normal parts of 
hepatectomy, taken at a distance from hemangiomas. Pathological specimens included post-burn 
cutaneous hypertrophic scars (n = 3), fibrotic liver tissue (n = 5), cirrhotic tissue (viral and alcoholic 
hepatitis) (n = 5), and hepatocellular carcinomas (n = 5). Tissue samples were fixed in 10% formalin 
and embedded in paraffin for immunohistochemistry or were immediately frozen in liquid 
nitrogen-cooled isopentane for confocal microscopy analysis. Sections were stained with antibodies 
against smoothelin, which is expressed exclusively by smooth muscle cells, and α-smooth muscle 
actin which is expressed by both smooth muscle cells and myofibroblasts.. 
 
RESULTS: In hypertrophic scars, α-smooth muscle actin was detected in vascular smooth muscle 
cells and in numerous myofibroblasts present in and around nodules whereas smoothelin was 
exclusively expressed in vascular smooth muscle cells. In normal liver, α-smooth muscle actin and 
smoothelin were exclusively expressed by the vascular smooth muscle cells. In fibrotic areas of the 
liver, myofibroblasts expressing α-smooth muscle actin were detected. Myofibroblasts 
co-expressing α-smooth muscle actin and smoothelin were observed and their number was slightly 
increased in parallel with the degree of fibrosis (absent in liver with mild or moderate fibrosis; 5 to 
10% positive in liver showing severe fibrosis). In cirrhotic septa, numerous myofibroblasts 
co-expressed α-smooth muscle actin and smoothelin (more than 50%). In hepatocellular carcinomas, 
the same pattern of expression for α-smooth muscle actin and smoothelin was observed in the 
stroma reaction surrounding the tumor and around tumoral cell plates. In all pathological liver 
samples, α-smooth muscle actin and smoothelin were co-expressed in vascular smooth muscle cells. 
 
CONCLUSION: During development of advanced liver fibrosis, a subpopulation of myofibroblast 
expressing smoothelin may be derived from vascular smooth muscle cells, illustrating the different 
cellular origins of myofibroblasts.  
 
© 2013 Baishideng. All rights reserved.   
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Core tip: In fibrotic conditions, it has been suggested that smooth muscle cells can acquire a 
myofibroblastic phenotype. To explore this hypothesis, we studied the expression of smoothelin, a 
specific marker of end-stage differentiation of smooth muscle cells, in cutaneous and hepatic 
fibrotic conditions using immunohistochemistry and confocal microscopy. We show here that 
during advanced liver fibrosis, a subpopulation of α-smooth muscle actin-expressing 
myofibroblasts also express smoothelin and thus may be derived from vascular smooth muscle cells. 
This finding, which illustrates the different potential cellular origins of the myofibroblasts involved 
in liver fibrogenesis, may represent an interesting tool to distinguish advanced stages of cirrhosis. 
 
Lepreux S, Guyot C, Billet F, Combe C, Balabaud C, Bioulac-Sage P, Desmoulière A.  
Smoothelin, a new marker to determine the origin of liver fibrogenic cells 
World J Gastroenterol 2013;   
Available from: URL: http://www.wjgnet.com/esps/   
DOI: http://dx.doi.org/10.3748/wjg.v19.i0.0000 
  
 
INTRODUCTION  
 
Smoothelin, a constituent of the smooth muscle cell cytoskeleton, has been described as a marker of 
end-stage differentiation of smooth muscle cells since it has been found only in contractile smooth 
muscle cells[1-3]. Smoothelin has two major isoforms in the adult, which are expressed in a tissue 
specific manner: i/ a 59 kDa isoform, smoothelin-A, which is expressed in visceral and urogenital 
tissues such as the digestive tract, bladder, and prostate; ii/ a 110 kDa isoform, smoothelin-B, which 
is expressed in the blood vessel wall[4]. Transient synthesis of a third smoothelin isoform has been 
detected in embryonic striated muscle cells in chicken[5]. In cultured smooth muscle cells, it has 
been shown that smoothelin colocalizes with α-smooth muscle actin stress fibres[3] and that 
smoothelin can bind to α-smooth muscle actin correlated  with a direct role of smoothelin in 
contraction[6]. In contrast, it was described that cells with smooth muscle cell-like features, such as 
myofibroblasts, do not express smoothelin[3]. Myofibroblasts are contractile cells which express 
α-smooth muscle actin[7]. These cells are involved in tissue repair processes and particularly, in 
extracellular matrix deposition and remodelling[8]. In normal connective tissues, myofibroblasts are 
rare[9]. After tissue injury, myofibroblasts appear and it is commonly accepted that most derive 
from locally recruited connective tissue fibroblasts[10]. In the liver, the most important cells involved 
in fibrogenesis are hepatic stellate cells and portal fibroblasts which are able to differentiate into 
myofibroblasts and are responsible for matrix deposition[11]. However, the involvement of different 
cell types with various origins, such as smooth muscle cells, circulating cells or bone 
marrow-derived cells has also been suggested in the establishment of liver fibrosis/cirrhosis[12-16]. 
However, the degree to which this process contributes to fibrosis remains a matter of intense debate 
and is likely to be context-dependent. In order to determine the possible contribution of smooth 
muscle cells to the appearance of myofibroblasts during fibrotic processes, we have studied the 
expression of smoothelin in different diseases that show myofibroblast involvement, i.e. post-burn 
cutaneous hypertrophic scars, liver fibrosis and cirrhosis, and hepatocellular carcinomas.  
MATERIALS AND METHODS  
 
Human liver samples and tissue processing  
Human tissue samples used in this study were selected from the files of the tissue bank of the 
Department of Pathology (CHU Bordeaux, Pellegrin Hospital, Bordeaux, France). Normal liver 
tissues (n = 3) were obtained from macroscopically normal parts liver from hepatectomy, taken at a 
distance from hemangiomas. Pathological specimens included post-burn cutaneous hypertrophic 
scars (n = 3), fibrotic liver tissue (n = 5) ranging from F1 to F3 stage according to the Metavir 
score[17], cirrhotic tissues (viral and alcoholic hepatitis) (n = 5), and hepatocellular carcinomas (n = 5). 
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin and processed for 
diagnostic purposes and immunohistochemistry, or were immediately frozen in liquid 
nitrogen-cooled isopentane for confocal microscopy analysis. The procedures were carried out in 
accordance with the European Guidelines for the use of human tissues.  
 
Immunohistochemistry and confocal microscopy  
Mouse monoclonal antibodies against smoothelin (IgG1 clone R4A, which reacts with smoothelin A 
and B, MUbio Products, Maastricht, The Netherlands), and α-smooth muscle actin (IgG2a clone 1A4, 
Dako SA, Trappes, France) were used. These two antibodies have been extensively used and their 
specificity has been clearly documented [1,18]. Immunohistochemistry was essentially performed as 
previously described[19]. Briefly, after incubation with the first antibody, the epitopes were detected 
using the Vectastain® ABC system (Vector Laboratories, Peterborough, UK) or the Envision™ 
system (DakoCytomation, Trappes, France), and diaminobenzidine as the color substrate. Slides 
were then counterstained with haematoxylin.  
For double immunofluorescence, cryostat sections were first incubated with the antibodies against 
smoothelin and α-smooth muscle actin, then with a TRITC-conjugated goat anti-mouse IgG1 
(Southern Biotech, Birmingham, AL) and an Alexa Fluor® 488 goat anti-mouse IgG2a (Molecular 
Probes, Eugene, OR). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI ). 
Specificity of staining was confirmed by incubation in non-immune serum and in the absence of the 
primary antibody. For immunohistochemistry, sections were examined with a Zeiss Axioplan 2 
microscope (Carl Zeiss Microscopy, Jena, Germany). Images were acquired with an AxioCam 
camera (Carl Zeiss Vision, Hallbergmoos, Germany) by means of the AxioVision image processing 
and analysis system (Carl Zeiss Vision). For double immunofluorescence, sections were analyzed 
with a confocal microscopy (LSM Meta 510, Carl Zeiss Microscopy). 
For quantitative evaluation of the staining, cell counting was performed in the septa of fibrotic and 
cirrhotic livers and in the stroma reaction of hepatocellular carcinoma. Vessels were not included in 
this evaluation. For each field, the ratio of the number of smoothelin-positive and α-smooth muscle 
actin-positive cells over the number of cells only expressing α-smooth muscle actin was calculated. 
The analysis was performed on an average of 10 fields/zone using the x40 objective. Only positive 
cells containing a nucleus were counted. 
 
 
RESULTS  
 
α-Smooth muscle actin and smoothelin expression in hypertrophic scars 
In many situations, hypertrophic scars develop significant contractile activity (due to the presence 
of myofibroblasts) (Fig. 1A), and are usually organized in a nodular pattern (Fig. 1B). By 
immunohistochemistry, α-smooth muscle actin was detected in blood vessel walls and in numerous 
myofibroblasts present in and around nodules (Fig. 1C) whereas smoothelin was exclusively shown 
in vessel walls (Fig. 1D). Our data showed that myofibroblasts present in hypertrophic scars do not 
express smoothelin.  
 
α-Smooth muscle actin and smoothelin expression in normal and pathological livers 
In normal liver, α-smooth muscle actin was exclusively expressed by the smooth muscle cells 
within the tunica media of portal arteries and veins and of centrolobular veins (Fig. 2A). The 
expression of smoothelin in normal liver was also detected in the smooth muscle cells of these 
vessels (Fig. 2B). Smoothelin and α-smooth muscle actin showed a similar distribution. 
In liver with mild or moderate fibrosis (F1-F2), myofibroblasts present in fibrotic areas clearly 
expressed α-smooth muscle actin but did not express smoothelin (data not shown). In liver showing 
severe fibrosis (F3), strong staining for α-smooth muscle actin was detected in myofibroblasts 
present in fibrotic areas (Fig. 2C). Weak expression of smoothelin was present in a few 
myofibroblasts (Fig. 2D). In cirrhotic liver (F4), myofibroblasts present in cirrhotic septa expressed 
high amounts of α-smooth muscle actin (Fig. 2E). Numerous myofibroblasts also expressed 
smoothelin (Fig. 2F). In all stages of liver fibrosis, α-smooth muscle actin and smoothelin were 
co-expressed in vascular smooth muscle cells (Fig. 2 C-F). 
The co-localization of α-smooth muscle actin and of smoothelin in the same cells was confirmed by 
double immunofluorescence (Fig. 3). All cells expressing smoothelin also expressed α-smooth 
muscle actin, including vascular smooth muscle cells and myofibroblasts. Moreover, a quantitative 
evaluation showed that in liver showing severe fibrosis (F3), 5 to 10% of myofibroblasts 
co-expressed α-smooth muscle actin and smoothelin. In cirrhotic septa, more than 50% of 
myofibroblasts co-expressed α-smooth muscle actin and smoothelin. 
In hepatocellular carcinomas, we observed the same expression pattern of α-smooth muscle actin 
and smoothelin in the stroma reaction surrounding the tumor (Fig. 4A and 4B). These two proteins 
were also expressed by fusiform pericyte-like cells between endothelial cells of the sinusoidal 
capillaries and tumoral cell plates (Fig. 4C and 4D).  
DISCUSSION  
 
In normal conditions, several cell types which have contractile properties express α-smooth muscle 
actin such as smooth muscle cells and to a lesser extent pericytes. Smooth muscle cells display a 
large variation in phenotype among and even within tissues and organs. Different patterns of 
marker expression reflect in part the heterogeneity of smooth muscle cell subpopulations and their 
phenotypic modulation[20]. Smoothelin, a recently described smooth muscle cell marker, illustrates 
these phenotypic features. Firstly, smoothelin expression varies with isoform A, expressed in 
visceral smooth muscle cells, and isoform B, expressed in vascular smooth muscle cells[4]. Secondly, 
smoothelin has been described as being expressed only by fully differentiated smooth muscle cells 
and not by proliferative or non-contractile smooth muscle cells[1]. Thirdly, visceral smoothelin 
expression is different according to the location of the smooth muscle cells within the organ. For 
example, in the digestive tract and urinary tract, most of the smooth muscle cells of the muscularis 
propia express smoothelin but the smooth muscle cells of the muscularis mucosae do not[21,22]. 
During fibrotic processes, it is assumed that it is mainly fibroblasts that are recruited and acquire a 
myofibroblastic phenotype, i.e. a smooth muscle cell-like phenotype. However, it has been 
suggested that smooth muscle cells can also contribute to the appearance of myofibroblasts. 
Similarly to smooth muscle cells, fully-differentiated myofibroblasts express α-smooth muscle actin 
and are contractile cells; in addition myofiboblasts are responsible for extracellular matrix 
deposition. Like myofibroblasts observed within bladder carcimoma[21], blood vessel adventitia[23] 
or the airway wall of patients with asthma[24], our study shows that myofibroblasts in cutaneous 
hypertrophic scars do not express smoothelin. In the skin, myofibroblasts mostly derive from 
locally-recruited connective tissue fibroblasts which prior to injury do not express α-smooth muscle 
actin or smoothelin[8]. These fibroblasts when transformed into myofibroblasts, express α-smooth 
muscle actin but not smoothelin. Additionally, it has been shown that, in hypertrophic scars, a 
population of fibrogenic circulating cells called fibrocytes, is recruited and participates in scar 
formation[25]. Here, we have shown that, in hypertrophic scars, myofibroblasts do not express 
smoothelin, which suggests that these myofibroblasts probably do not derive from local smooth 
muscle cells. However, our study shows that infibrotic liver disease s, myofibroblasts can express 
smoothelin. Double immunofluorescence and confocal analysis confirmed the co-expression of 
α-smooth muscle actin and smoothelin in the same cells. This expression is stronger in parallel with 
the progression and the chronicity of the fibrotic lesion: that is there are more 
smoothelin-expressing myofibroblasts within advanced stages of fibrosis or cirrhosis than in the 
first stages of fibrosis. Smoothelin expression may thus appear gradually during fibrosis 
development; therefore smoothelin could represent a good marker for evaluating the prognosis of 
liver fibrosis. In the liver, numerous cell types can be recruited and acquire a myofibroblastic 
phenotype; generally these are fibroblasts within the portal tract and hepatic stellate cells in the 
space of Disse[11]. As shown here, these cells do not express smoothelin. However, myofibroblasts 
can also originate from the smooth muscle cells present in portal vessels and centrolobular veins[11], 
which, as described here, express smoothelin. In chronic hepatic schistosomiasis, it has been 
suggested that smooth muscle cells from the artery and vein tunica media are involved in portal 
fibrogenesis that occurs in this pathology[12]. In the experimental model of porcine serum-induced 
fibrosis in rats, mesenchymal cells, located around the centrolobular vein, called second layer cells, 
participate in the formation of fibrotic septae [26]. The expression of smoothelin within smooth 
muscle cells can also vary. In early atherosclerosic lesions, smoothelin expression decreases in the 
vicinity of the affected area[27,28] but, when the plaques become “quiescent”, smoothelin expression 
can be detected again[2]. Finally, we cannot exclude that the expression of smoothelin within septal 
myofibroblastic cells is a residual smooth muscle feature, underlining the possible smooth muscle 
cell origin of a subpopulation of myofibroblasts. Lastly, tumoral stroma is the connective tissue 
surrounding the tumoral cells[29]. No smoothelin-expressing stromal cells were described in 
published studies about bladder carcinoma[21,30]. In hepatocellular carcinoma, we show that 
numerous α-smooth muscle actin expressing myofibroblasts in the stroma reaction also express 
smoothelin, underlining the possible smooth muscle origin of these myofibroblasts. Surprisingly, 
we have also shown in hepatocellular carcinomas, that cells located between endothelial cells and 
tumoral hepatocytes express α-smooth muscle actin and smoothelin. Pericytes and hepatic stellate 
cells, also termed liver-specific pericytes[31,32], can express α-smooth muscle actin but not 
smoothelin[2]. This pattern of smoothelin expression, which was not found in fibrotic liver, 
illustrates the complete reorganization of the capillarized liver sinusoids during tumor 
development with the appearance of specific cells, and may represent an additional feature to 
diagnose hepatocellular carcinomas. In summary, we can hypothesize that during liver fibrosis, a 
subpopulation of myofibroblasts express smoothelin. These myofibroblasts may be derived from 
smooth muscle cells coming from vascular walls, which are recruited to participate in the fibrotic 
process. These cells expressing smoothelin are recruited in advanced stages of cirrhosis when a 
significant vascular reorganization occurs, including portovenous and arteriovenous shunting; 
therefore, smoothelin could be an interesting feature to distinguish advanced stages of cirrhosis. In 
addition, in hepatocellular carcinomas, smoothelin expression shows a very specific pattern. These 
data again illustrate the different cellular origins of the so-called myofibroblastic cells involved in 
liver fibrogenesis.  
 
COMMENTS 
Background 
Myofibroblasts are fibrogenic and contractile cells involved in remodeling and healing processes. In 
most organs, myofibroblasts are rare in normal physiological conditions.. After tissue injury, 
myofibroblasts appear, deriving from local stromal cells such as resident fibroblasts or organ 
specific stromal cells such as hepatic stellate cells in the liver. 
Research frontiers 
In order to explore the origin of myofibroblasts, we studied the expression of smoothelin, a 
constituent of the smooth muscle cell cytoskeleton, in normal and fibrotic liver, hepatocellular 
carcinoma and in cutaneous hypertrophic scar. Immunohistochemistry was used to identify 
smoothelin-expressing cells. 
Innovations and breakthroughs 
This is the first study exploring smoothelin expression in normal liver, fibrotic liver and 
hepatocellular carcinoma. The results show an increase of expression correlated with the degree of 
fibrosis suggesting the progressive involvement of resident smooth muscle cells in myofibroblast 
recruitment. In hepatocellular carcinoma, smoothelin is expressed by pericyte-like cells between the 
endothelial cells of the capillaries and the tumoral cell plates. 
Applications  
This preliminary study underlines that tracing the origin of myofibroblasts may be useful to 
evaluate the degree of fibrosis in the liver and the level of reorganization in hepatocellular 
carcinomas. 
Terminology 
Smoothelin is a constituent of the smooth muscle cell cytoskeleton. It has been described as a 
marker of end-stage differentiation of smooth muscle cells since expression has been found only in 
contractile smooth muscle cells. 
Peer review 
This is a good descriptive study in which authors explore the expression pattern of a smooth muscle 
marker called smoothelin within normal, fibrotic and tumoral liver as well as cutaneous 
hypertrophic scar. The results are interesting and suggest that smoothelin expression is increased 
with the degree of fibrosis, allowing the evaluation of the transition between fibrosis and cirrhosis. 
Moreover, in hepatocellular carcinoma, smoothelin is expressed by some stromal cells present 
beneath endothelial cells of the capillary surrounding the tumoral cell plates and this distinctive 
feature could be useful for hepatocellular diagnosis. 
 
REFERENCES  
1  van der Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ. Smoothelin, a novel 
cytoskeletal protein specific for smooth muscle cells. J Cell Biol 1996; 134: 401-411 [PMID: 
8707825]  
2  van der Loop FT, Gabbiani G, Kohnen G, Ramaekers FC, van Eys GJ. Differentiation of 
smooth muscle cells in human blood vessels as defined by smoothelin, a novel marker for the 
contractile phenotype. Arterioscler Thromb Vasc Biol 1997; 17: 665-671 [PMID: 9108778 DOI: 
10.1161/01.ATV.17.4.665]  
3  Christen T, Verin V, Bochaton-Piallat M, Popowski Y, Ramaekers F, Debruyne P, Camenzind 
E, van Eys G, Gabbiani G. Mechanisms of neointima formation and remodeling in the porcine 
coronary artery. Circulation 2001; 103: 882-888 [PMID: 11171799 DOI: 10.1161/01.CIR.103.6.882]  
4  van Eys GJ, Voller MC, Timmer ED, Wehrens XH, Small JV, Schalken JA, Ramaekers FC, van 
der Loop FT. Smoothelin expression characteristics: development of a smooth muscle cell in 
vitro system and identification of a vascular variant. Cell Struct Funct 1997; 22: 65-72 [PMID: 
9113392 DOI: 10.1247/csf.22.65]  
5  Deruiter MC, Rensen SS, Coolen GP, Hierck BP, Bergwerff M, Debie WM, Gittenberger-De 
Groot AC, Van Eys GJ. Smoothelin expression during chicken embryogenesis: detection of an 
embryonic isoform. Dev Dyn 2001; 221: 460-463 [PMID: 11500983 DOI: 10.1002/dvdy.1156]  
6  Niessen P, Rensen S, van Deursen J, De Man J, De Laet A, Vanderwinden JM, Wedel T, Baker 
D, Doevendans P, Hofker M, Gijbels M, van Eys G. Smoothelin-A is essential for functional 
intestinal smooth muscle contractility in mice. Gastroenterology 2005; 129: 1592-1601 [PMID: 
16285958 DOI:10.1053/j.gastro.2005.08.018]  
7  Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and 
mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-363 
[PMID: 11988769 DOI:10.1038/nrm809]  
8  Sarrazy V, Billet F, Micallef L, Coulomb B, Desmoulière A. Mechanisms of pathological 
scarring: role of myofibroblasts and current developments. Woud Rep Regen 2011; 19: S10-15 
[PMID: 21793960] [DOI: 10.1111/j.1524-475X.2011.00708.x]  
9  Schmitt-Gräff A, Desmoulière A, Gabbiani G. Heterogeneity of myofibroblast phenotypic 
features: an example of fibroblastic cell plasticity. Virchows Arch 1994; 425: 3-24 [PMID: 
7921410]  
10  Higashiyama R, Nakao S, Shibusawa Y, Ishikawa O, Moro T, Mikami K, Fukumitsu H, Ueda 
Y, Minakawa K, Tabata Y, Bou-Gharios G, Inagaki Y. Differential contribution of dermal 
resident and bone marrow-derived cells to collagen production during wound healing and 
fibrogenesis in mice. J Invest Dermatol 2011; 131: 529-536 [PMID: 20962852 DOI: 
10.1038/jid.2010.314]  
11  Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmoulière A. 
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem 
Cell Biol 2006; 38: 135-151 [PMID: 16257564 DOI:10.1016/j.biocel.2005.08.021]  
12  Andrade ZA, Guerret S, Fernandes AL. Myofibroblasts in schistosomal portal fibrosis of man. 
Memorias do Instituto Oswaldo Cruz 1999; 94: 87-93 [PMID: 10029917]  
13  Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, 
Brenner DA. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J 
Hepatol 2006; 45: 429-438 [PMID: 16846660 DOI:10.1016/j.jhep.2006.04.014]  
14  Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant 
proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. 
Gastroenterology 2004; 126: 955-963 [PMID: 15057733 DOI:10.1053/j.gastro.2004.02.025]  
15  Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, 
Iredale JP, Forbes SJ. The bone marrow functionally contributes to liver fibrosis. 
Gastroenterology 2006; 130: 1807-1821 [PMID: 16697743 DOI:10.1053/j.gastro.2006.01.036]  
16  Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel 
M, Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective 
tissue remodeling. Am J Pathol 2012; 180: 1340-1355 [PMID: 22387320 DOI: 
10.1016/j.ajpath.2012.02.004]  
17  Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The 
METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 
10.1002/hep.510240201]  
18  Skalli O, Vandekerckhove J, Gabbiani G. Actin-isoform pattern as a marker of normal or 
pathological smooth-muscle and fibroblastic tissues. Differentiation 1987; 33: 232-238 [PMID: 
3596085]  
19  Lepreux S, Bioulac-Sage P, Gabbiani G, Sapin V, Housset C, Rosenbaum J, Balabaud C, 
Desmoulière A. Cellular retinol-binding protein-1 expression in normal and fibrotic/cirrhotic 
human liver: different patterns of expression in hepatic stellate cells and (myo)fibroblast 
subpopulations. J Hepatol 2004; 40: 774-780 [PMID: 15094224 DOI: 10.1016/j.jhep.2004.01.008] 
20  van Eys GJ, Niessen PM, Rensen SS. Smoothelin in vascular smooth muscle cells. Trends 
Cardiovasc Med 2007; 17: 26-30 [PMID: 17210475 DOI: 10.1016/j.tcm.2006.11.001]  
21  Council L, Hameed O. Differential expression of immunohistochemical markers in bladder 
smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and 
vimentin in staging of bladder carcinoma. Mod Pathol 2009; 22: 639-650 [PMID: 19252475 DOI: 
10.1038/modpathol.2009.9]  
22  Montani M, Thiesler T, Kristiansen G. Smoothelin is a specific and robust marker for 
distinction of muscularis propia and muscularis mucosae in the gastrointestinal tract. 
Histopathology 2010; 57: 244-249 [PMID: 20716166 DOI: 10.1111/j.1365-2559.2010.03618.x]  
23  Maeng M, Mertz H, Nielsen S, van Eys GJ, Rasmussen K, Espersen GT. Adventitial 
myofibroblasts play no major role in neointima formation after angioplasty. Scand Cardiovasc J 
2003; 37: 34-42 [PMID: 12745801]  
24  Nam Y-H, Lee S-K, Sammut D, Davies DE, Howarth PH. Preliminary study of the cellular 
characteristics of primary bronchial fibroblasts in patients with asthma: expression of 
 -smooth muscle actin, fibronectin containing extra type III domain A, and smoothelin. J 
Investig Allergol Clin Immunol 2012; 22: 20-27 [PMID: 22448450]  
25  Yang L, Scott P G, Dodd C, Medina A, Jiao H, Shankowsky HA, Ghahary A, Tredget EE. 
Identification of fibrocytes in postburn hypertrophic scar. Wound Rep Regen 2005; 13: 398-404 
[PMID: 16008729 DOI: 10.1111/j.1067-1927.2005.130407.x]  
26  Bhunchet E, Wake K. Role of mesenchymal cell populations in porcine serum-induced rat 
liver fibrosis. Hepatology 1992; 16: 1452-1473 [PMID: 1446899 DOI: 10.1002/hep.1840160623]  
27  Verhamme P, Quarck R, Hao H, Knaapen M, Dymarkowski S, Bernar H, Van Cleemput J, 
Janssens S, Vermylen J, Gabbiani G, Kockx M, Holvoet P. Dietary cholesterol withdrawal 
reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. 
Cardiovasc Res 2002; 56: 135-144 [PMID: 12237174 DOI: 10.1016/S0008-6363(02)00515-1]  
28  Tharp DL, Wamhoff BR, Turk JR, Bowles DK. Upregulation of intermediate-conductance 
Ca2+-activated K+ channel (IKCa1) mediates phenotypic modulation of coronary smooth 
muscle. Am J Physiol Heart Circ Physiol 2006; 291: H2493-2503 [PMID: 16798818 DOI: 
10.1152/ajpheart.01254.2005]  
29  Otranto M, Sarrazy V, Bonté F, Hinz B, Gabbiani G, Desmoulière A. The role of the 
myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012; 6: 203-219 [PMID: 22568985 
DOI: 10.4161/cam.20377]  
30  Paner GP, Shen SS, Lapetino S, Venkataraman G, Barkan GA, Quek ML, Ro JY, Amin MB. 
Diagnostic utility of antibody to smoothelin in the distinction of muscularis propia from 
muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging 
of invasive urothelial carcinoma. Am J Surg Pathol 2009; 33: 91-98 [PMID: 18936687 DOI: 
10.1097/PAS.0b013e3181804727]  
31 Pinzani M. Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte. J Hepatol  
1995; 22: 700-706 [PMID: 7560865 DOI: 10.1016/0168-8278(95)80227-4] 
32 Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbé E, Vermoesen A. Structure and function 
of sinusoidal lining cells in the liver. Toxicol Pathol 1996; 24: 100-111 [PMID: 8839287 DOI: 
10.1177/019262339602400114] 
FIGURE LEGENDS  
 
Figure 1.  
α-Smooth muscle actin and smoothelin expression in cutaneous hypertrophic scar.  
A: Following a burn injury, a retractile hypertrophic scar was observed (from Vincent Casoli, Plastic 
Surgery and Burns Unit, University Hospital of Bordeaux, France). B: Hematoxylin and eosin 
staining shows typical hypertrophic scar architecture with nodules (N) surrounded by cell bundles 
(CB). C: α-Smooth muscle actin is expressed in vascular smooth muscle cells and myofibroblasts 
both in and around nodules. D: Smoothelin is only expressed by vascular tunica media smooth 
muscle cells.  
 
Figure 2.  
α-Smooth muscle actin and smoothelin expression in normal, fibrotic and cirrhotic liver. 
A and B: In normal liver, α-smooth muscle actin (A) and smoothelin (B) show similar expression in 
tunica media smooth muscle cells of portal arteries and veins and of centrolobular veins. C and D: 
In severe fibrosis, myofibroblasts express high amounts of α-smooth muscle actin (C); while 
smoothelin is only expressed at low levels (D) (α-smooth muscle actin and smoothelin are 
coexpressed in vascular smooth muscle cells). E and F: In cirrhotic liver, myofibroblasts express α--
smooth muscle actin in fibrotic septae (E) and numerous myofibroblasts also express smoothelin (F); 
however, smoothelin expression is lower as compared with α-smooth muscle actin expression 
(insert). α-smooth muscle actin and smoothelin are co-expressed in vascular tunica media smooth 
muscle cells (F).  
 
Figure 3. 
Cellular co-localization of α-smooth muscle actin and smoothelin in fibrotic liver. 
A: α-Smooth muscle actin expression (green). B: Smoothelin expression (red). D: merged (nuclei are 
stained with DAPI). Smoothelin-expressing cells also express α-smooth muscle actin. 
 
Figure 4.  
α-Smooth muscle actin and smoothelin expression in hepatocellular carcinoma. 
A and B: α-Smooth muscle actin (A) and smoothelin (B) are expressed similarly in the stroma 
reaction surrounding the tumor (arrows) and around tumoral hepatocytes. C and D: α-Smooth 
muscle actin (C) and smoothelin (D) are expressed by pericyte-like cells underlying capillaries 
between tumoral hepatocytes.  
